1. For a recent review, see: Doble, A. Pharmacol. Ther. 1999, 81, 163, and references cited therein.
2. Choi, D. W. Neuron, 1988, 1, 623. Sheardown, M. J.; Nielsen, E. O.; Hansen, A. J.; Jacobsen, P.; Honore, T. Science, 1990, 247, 571. Gill, R.; Brazell, C.; Woodruff, G. N.; Kemp, J. A. Br. J. Pharmacol., 1991, 103, 2030. Weiss, J. H.; Koh, J-Y.; Baimbridge, K. G.; Choi, D. W. In Vitro Neurology 1990, 40, 1288. Klockgether, T.; Turski, L.; Honore, T.; Zhang, Z.; Gash, D. M.; Kurlan, R.; Greenmyre, J. T. Ann. Neurol., 1991, 30, 717. Lipton, S. A., Rosenberg, P. A. N. Engl. J. Med., 1994, 330, 613. Chapman, A. G.; Smith, S. E.; Meldrum, B. S. Epilepsy Res., 1991, 9, 92 and references cited therein.
3. 6-(1H-Imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA-type non-NMDA receptor
4. Turski, L.; Huth, A.; McDonald, F.; Schneider, H. H.; Neuhaus, R.; Dyrks, T.; Bresink, I.; Ottow, E. 27th Annual Meeting of the Society for Neuroscience, New Orleans, October 25–30, 1997, poster 946.18.
5. (3SR,4aRS,6RS,8aRS)-6-[2-(1H-Tetrazol-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid: a structurally novel, systemically active, competitive AMPA receptor antagonist